CorVel Corporation (CRVL) - Q2 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025, and the six months ended on that date. CorVel Corporation is an independent nationwide provider of medical cost containment and managed care services, primarily serving workers' compensation, automobile insurance, and group health insurance payors. The company operates in a single reportable segment: managed care, which includes patient management and network solutions service lines.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenues | $239.6 million | $224.4 million | $474.4 million | $436.1 million |
| Net Income | $27.9 million | $23.4 million | $55.1 million | $45.0 million |
| Diluted EPS | $0.54 | $0.45 | $1.06 | $0.87 |
| Gross Margin | 24.3% | 22.6% | 24.2% | 22.7% |
| Operating Cash Flow (YTD) | $80.0 million (vs. $62.7 million YTD 2024) | |||
| Cash & Equivalents | $207.5 million (as of Sept 30, 2025) | |||
| Total Liabilities | $248.9 million (No long-term debt reported) |
Material Changes vs. Prior Period
- Revenue Growth: Q2 revenue increased 7% year-over-year, driven primarily by a 15% increase in Network Solutions services ($88.8M vs. $77.2M). Patient Management services grew 2%.
- Profitability Expansion: Net income rose 19% in Q2 and 23% YTD. Gross margin expanded to 24.3% in Q2 from 22.6% in the prior year, reflecting improved efficiency and higher revenue per bill in network solutions.
- Expense Management: General and administrative (G&A) expenses remained flat in Q2 (+1%) and grew only 3% YTD, representing 9.3% of revenue in Q2 (down from 9.8% prior year).
- Share Count: Diluted weighted average shares decreased slightly (0.6% in Q2) due to ongoing share repurchases partially offset by option exercises.
Guidance, Outlook, and Risks
- Management Commentary: Management attributes growth to increased activity with existing customers in network solutions and enhanced bill review programs. The company expects G&A expenses to remain between 9% and 11% of revenues in future quarters.
- Capital Allocation: The company continues its stock repurchase program. In Q2, it repurchased 143,774 shares for $12.8 million. As of September 30, 2025, approximately 2.3 million shares remain available under the program.
- Recent Acquisition: In Q2 2025, CorVel acquired a privately held technology firm to enhance its bill review process, adding proprietary tools and intellectual property.
- Risks: Key risks include potential declines in workers' compensation claims due to economic shifts, increased competition, inflationary pressure on labor costs, and cybersecurity threats. The company also notes regulatory risks regarding healthcare cost containment techniques and data privacy.
- Leadership Change: Brian S. Nichols replaced Brandon T. O'Brien as Chief Financial Officer effective September 10, 2025.
Investor Verification Checklist
- Revenue Mix: Verify the sustainability of the 15% growth in Network Solutions services versus the slower 2% growth in Patient Management.
- Margin Sustainability: Assess whether the 1.7% expansion in gross margin is driven by pricing power or temporary cost efficiencies.
- Share Repurchase Impact: Confirm the remaining authorization under the buyback program and the company's commitment to continue repurchases given the current cash balance of $207.5 million.
- Acquisition Integration: Monitor the financial impact and integration progress of the Q2 technology acquisition.
- Regulatory Environment: Review updates on state-level workers' compensation laws that could impact demand for cost containment services.